Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2002 • 6,505 citations

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

2001 • 6,133 citations

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

2009 • 3,503 citations

Hepatitis C Virus Infection

2001 • 2,979 citations

Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

2004 • 2,888 citations

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

2011 • 2,514 citations

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

2011 • 2,404 citations

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

2009 • 2,138 citations

Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

1998 • 2,112 citations

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

2009 • 1,812 citations

Telaprevir for Retreatment of HCV Infection

2011 • 1,559 citations

The lipid droplet is an important organelle for hepatitis C virus production

2007 • 1,186 citations

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

2009 • 1,176 citations

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

2009 • 1,095 citations

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

2011 • 1,089 citations

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

2009 • 1,025 citations

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

2011 • 749 citations

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

2010 • 734 citations

Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir

2007 • 620 citations

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

2012 • 598 citations

Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study

2006 • 401 citations

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

2007 • 383 citations

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

2011 • 338 citations

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

2010 • 330 citations

An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response

2010 • 323 citations

Hepatitis C virus resistance to protease inhibitors

2011 • 297 citations

Antiviral strategies in hepatitis C virus infection

2012 • 280 citations

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

2011 • 263 citations

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C

2007 • 258 citations

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

2008 • 213 citations

Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections

2011 • 182 citations

Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies

2010 • 178 citations

Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C

2010 • 171 citations

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C

2011 • 157 citations

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

2009 • 156 citations

[Introduction and comments on EASL clinical practice guidelines: management of hepatitis C virus infection].

2011 • 152 citations

Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals

2011 • 147 citations

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

2008 • 131 citations

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

2011 • 129 citations

Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate

2010 • 117 citations

Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy

2010 • 114 citations

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C

2011 • 112 citations

Hepatitis C Virus: Assembly and Release of Virus Particles

2010 • 107 citations

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study

2012 • 105 citations

<scp>UK</scp> consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis <scp>C</scp> infected patients

2012 • 92 citations

12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY

2011 • 91 citations

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

2012 • 88 citations

New Insights into Structure and Replication of the Hepatitis C Virus and Clinical Implications

2010 • 76 citations

Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment

2011 • 72 citations

13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY

2011 • 70 citations

Initial management of a major burn: I—overview

2004 • 68 citations

The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus

2009 • 51 citations

477 ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES

2011 • 46 citations

11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS

2012 • 40 citations

476 ANEMIA DURING TREATMENT WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN WITH OR WITHOUT BOCEPREVIR IS ASSOCIATED WITH HIGHER SVR RATES: ANALYSIS OF PREVIOUSLY UNTREATED AND PREVIOUS-TREATMENT-FAILURE PATIENTS

2011 • 38 citations

Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy

2011 • 32 citations

An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C

2011 • 31 citations

50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS

2012 • 28 citations

Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-Responder Patients Treated With Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the Realize Study

2011 • 21 citations

Telaprevir in combination with peginterferon Alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis

2012 • 18 citations

Anemia During Treatment With Peginterferon Alfa-2B/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous-Treatment-Failure Patients

2011 • 13 citations

Peginterferon and Dose-Titrated Ribavirin for Hepatitis C-Associated Nephrotic Membranoproliferative Glomerulonephritis Type 1

2005 • 8 citations

Hepatitis C: screening, treatment and prevention practical guidelines.

2003 • 7 citations